Direct Answer
Insulet Corporation reports revenue across 3 product and service lines in its fiscal 2025 Form 10-K. U.S.Omnipod is the largest, with $1.9 billion of revenue (71% of the total), followed by International Omnipod at $754 million (28%). 72% of revenue came from the United States.
How Does Insulet Corporation Make Money?
U.S.Omnipod supplies 71% of revenue, so Insulet Corporation's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, International Omnipod grew fastest (+44.1%) and Drug Delivery slowest (-12.3%), so the revenue mix tilts toward International Omnipod while that gap lasts.
| Product or service | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| U.S.Omnipod | $1.9 billion | $1.5 billion | 70.9% | 27.2% |
| International Omnipod | $754 million | $523 million | 27.9% | 44.1% |
| Drug Delivery | $34 million | $39 million | 1.3% | -12.3% |
Where Does Insulet Corporation's Revenue Come From?
Regions follow the definitions in the filing; most companies assign revenue by customer location.
| Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| United States | $2.0 billion | $1.5 billion | 72.2% | 26.2% |
| Outside the United States | $754 million | $523 million | 27.9% | 44.1% |
What the Segment Figures Do Not Show
The rows above add up to 100% of Insulet Corporation's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.
Where These Numbers Come From
Every figure on this page is a value Insulet Corporation reported in the segment note and revenue disclosures of its Form 10-K filed February 18, 2026 (accession 0001145197-26-000028), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.
Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.
Frequently Asked Questions
What are Insulet Corporation's main products and services?
In its fiscal 2025 Form 10-K, Insulet Corporation reports revenue for U.S.Omnipod, International Omnipod and Drug Delivery.
Which part of Insulet Corporation brings in the most revenue?
U.S.Omnipod, with $1.9 billion of revenue in fiscal 2025, or 71% of the total.
How much of Insulet Corporation's revenue comes from outside the United States?
28% in fiscal 2025, by the geographic breakdown Insulet Corporation reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies.